Dr. Jeffery Cummings (Brain Health) and other members of a joint European Union/United States Task Force recently published, “The Future of Anti-Amyloid Trials,” in the Journal of Prevention and Alzheimer’s Disease. The authors analyze the impact of multiple clinical trials that recently ended for a variety of reasons on the Alzheimer's disease clinical research enterprise. The task force concludes the study of amyloid proteins, while complex, remains a worthwhile undertaking and should not be the only target of clinical trials.They offer several recommendations in the trial design to optimize the potential benefits and reduce potential risks to participants as much as possible.